585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Abstract

In IPATential150 (NCT03072238), ipat + abi as first-line mCRPC treatment (tx) significantly reduced the risk for disease worsening or death vs placebo (pbo) + abi in patients (pts) with tumours with PTEN loss status by IHC (HR, 0.77; 95% CI: 0.61, 0.98; P = 0.034) but not in the ITT population (de Bono ESMO 2020). Ipat + abi had a safety profile consistent with each agent’s known toxicities. Here, we further characterise the nature and manageability of AEs associated with ipat and abi from IPATential150, the first Ph III trial of AKT plus androgen biosynthesis inhibition for mCRPC.